Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06116890 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Kyowa Kirin Co..

Active
Registry status
Phase 2
Development phase
180
Enrollment target
20
Study locations

NCT06116890 is a Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD) that is active but no longer recruiting, run by Kyowa Kirin Co.. The registered enrollment target is 180 participants, roughly in line with the 188-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06116890, a Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD), is active but no longer recruiting, sponsored by Kyowa Kirin Co..

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • DRUG Aflibercept Injection
  • DRUG KHK4951

Study Locations (20)

Florida

  • Blue Ocean Clinical Research West - Clearwater
  • Florida Eye Associates - Melbourne
  • Eye Associates of Pinellas - Pinellas Park
  • Ft. Lauderdale Eye Institute - Plantation
  • Retina Vitreous Associates of Florida - Saint Petersburg - St. Petersburg
  • Southern Vitreoretinal Associates - Tallahassee
  • Center for Retina and Macular Disease - Ophthalmology - Winter Haven

California

  • Win Retina - Arcadia
  • Retina Vitreous Associates Medical Group - Beverly Hills
  • The Retina Partners - Encino
  • Salehi Retina Institute, Inc - Huntington Beach
  • Payam Amini - Pasadena

Arizona

  • Barnet Dulaney Perkins Eye Center - Phoenix - Mesa
  • Retina Associates Southwest, P.C. - Tucson

Colorado

  • Retina Consultants of Southern CO - Colorado Springs

Georgia

  • Southeast Retina Center - Augusta

Massachusetts

  • Massachusetts Eye and Ear - Boston

Michigan

  • Associated Retinal Consultants (ARC) P.C. - Opthalmology - Royal Oak

Nevada

  • Sierra Eye Associates - Reno

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-01-31
Est. Completion 2026-09-30
Phase Phase 2

Sponsor

Kyowa Kirin Co.

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06116890

The ClinicalTrials.gov registry entry for NCT06116890 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept Injection is the first listed.

NCT06116890 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06116890 about?

NCT06116890 is a clinical study titled "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration". The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

What is the current status of trial NCT06116890?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-01-31. Estimated completion is 2026-09-30.

What conditions does trial NCT06116890 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).

What interventions are being tested in trial NCT06116890?

The interventions under investigation include: Aflibercept Injection (DRUG), KHK4951 (DRUG).

Who is sponsoring clinical trial NCT06116890?

This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06116890 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration (nAMD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.